At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLYS Mineralys Therapeutics, Inc.
Not Yet Opened 01-09 16:00:00 EST
33.37
+0.24
+0.72%
盘后33.81
+0.44+1.32%
18:25 EST
High33.92Low32.71Vol1.36M
Open33.27D1 Closing33.13Amplitude3.65%
Mkt Cap2.64BTradable Cap1.86BTotal Shares79.14M
T/O45.19MT/O Rate2.44%Tradable Shares55.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mineralys Therapeutics Inc - Filed Nda for Lorundrostat to U.S. FDA in Late 2025
THOMSON REUTERS  ·  01-06
Mineralys Therapeutics Inc - Filed Nda for Lorundrostat to U.S. FDA in Late 2025
Mineralys Therapeutics Inc - Co Remains on Track to Report Topline Results From Phase 2 Explore-Osa Trial in Q1 2026
THOMSON REUTERS  ·  01-06
Mineralys Therapeutics Inc - Co Remains on Track to Report Topline Results From Phase 2 Explore-Osa Trial in Q1 2026
Mineralys Therapeutics Submits NDA for Lorundrostat to FDA
Reuters  ·  01-06
Mineralys Therapeutics Submits NDA for Lorundrostat to FDA
Did JAMA’s “Research of the Year” Spotlight on Lorundrostat Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative?
Simply Wall St.  ·  2025-12-21
Did JAMA’s “Research of the Year” Spotlight on Lorundrostat Just Shift Mineralys Therapeutics’ (MLYS) Investment Narrative?
Mineralys Therapeutics Inc : Bofa Global Research Raises Price Objective to $46 From $43
THOMSON REUTERS  ·  2025-12-19
Mineralys Therapeutics Inc : Bofa Global Research Raises Price Objective to $46 From $43
How Investors May Respond To Mineralys Therapeutics (MLYS) After $287.5 Million Upsized Capital Raise and New Institutional Backing
Simply Wall St.  ·  2025-12-01
How Investors May Respond To Mineralys Therapeutics (MLYS) After $287.5 Million Upsized Capital Raise and New Institutional Backing
BRIEF-Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Reuters  ·  2025-11-27
BRIEF-Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Director and 10% Owner Brian Taylor Slingsby Reports Disposal of Mineralys Therapeutics Inc. Common Shares
Reuters  ·  2025-11-22
Director and 10% Owner Brian Taylor Slingsby Reports Disposal of Mineralys Therapeutics Inc. Common Shares
Mineralys Therapeutics Q3 EPS USD -0.52
Reuters  ·  2025-11-20
Mineralys Therapeutics Q3 EPS USD -0.52
Mineralys Therapeutics Shares Fall Following Executives' Stock Sale
MT Newswires Live  ·  2025-11-15
Mineralys Therapeutics Shares Fall Following Executives' Stock Sale
Mineralys Therapeutics falls -13.9%
TIPRANKS  ·  2025-11-14
Mineralys Therapeutics falls -13.9%
Mineralys Therapeutics Director Daphne Karydas Reports Disposal of Common Shares
Reuters  ·  2025-11-14
Mineralys Therapeutics Director Daphne Karydas Reports Disposal of Common Shares
Evercore ISI Keeps Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  2025-11-12
Evercore ISI Keeps Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Stock Track | Mineralys Therapeutics Soars 5.22% as Multiple Analysts Raise Price Targets
Stock Track  ·  2025-11-11
Stock Track | Mineralys Therapeutics Soars 5.22% as Multiple Analysts Raise Price Targets
Stifel Nicolaus Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  2025-11-11
Stifel Nicolaus Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
LifeSci Capital Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  2025-11-11
LifeSci Capital Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Wells Fargo Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  2025-11-11
Wells Fargo Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. : Wells Fargo Raises Target Price to $55 From $50
THOMSON REUTERS  ·  2025-11-11
Mineralys Therapeutics, Inc. : Wells Fargo Raises Target Price to $55 From $50
Mineralys Therapeutics files automatic mixed securities shelf
TIPRANKS  ·  2025-11-11
Mineralys Therapeutics files automatic mixed securities shelf
Mineralys Therapeutics Inc - in Addition, Offering of up to $300 Mln of Common Stock
THOMSON REUTERS  ·  2025-11-11
Mineralys Therapeutics Inc - in Addition, Offering of up to $300 Mln of Common Stock

Introduction

Company Name.
Mineralys Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Issue price:
--